Department of Medicine, Icahn School of Medicine at Mount Sinai/NYC H&H Queens, NY, USA.
Oncology Department, Southend University Hospital, Mid and South Essex NHS Foundation Trust, ESSEX, UK.
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):447-454. doi: 10.1016/j.dsx.2021.02.009. Epub 2021 Feb 10.
/Aim: Various reports of the occurrence of type 1 diabetes mellitus (T1DM) in patients with COVID-19 have been published, denoting an association between both diseases. Therefore, we conducted this systematic review to summarize the prevalence of T1DM in COVID-19 patients and to identify the clinical presentations and outcomes in this patient population.
Up to 10/27/2020, Medline, Embase, cochrane and google scholar databases were searched for original studies investigating the association between COVID-19 and T1DM. A manual search was conducted to identify missing studies. The quality of included studies was analyzed by the National Institute of Health (NIH) risk of bias tool. Outcomes included length of hospital stay, hospitalization, intensive care unit (ICU) admission, diabetic ketoacidosis (DKA), severe hypoglycemia, and death.
Fifteen studies were included in the qualitative analysis. Included studies reported data of both adult and pediatric patients. The prevalence of T1DM in COVID-19 patients ranged from 0.15% to 28.98%, while the rate of COVID-19 in patients with T1DM ranged from 0% to 16.67%. Dry cough, nausea, vomiting, fever and elevated blood glucose levels were the most commonly reported presentations. The investigated outcomes varied widely among studied populations.
The prevalence of T1DM in patients with COVID-19 ranged from 0.15% to 28.98%. The most common presentation of COVID-19 in patients with T1DM included fever, dry cough, nausea and vomiting, elevated blood glucose and diabetic ketoacidosis. The outcomes of COVID-19 in terms of length of hospital stay, hospitalization, ICU admission, DKA rate, and severe hypoglycemia were reported variably in included studies. Due to the heterogeneous study populations and the presence of many limitations, more studies are still warranted to reach a definitive conclusion.
目的：已有多项关于 COVID-19 患者发生 1 型糖尿病（T1DM）的报告，表明这两种疾病之间存在关联。因此，我们进行了这项系统综述，以总结 COVID-19 患者中 T1DM 的患病率，并确定该患者人群的临床表现和结局。
截至 2020 年 10 月 27 日，检索了 Medline、Embase、Cochrane 和 Google Scholar 数据库，以寻找调查 COVID-19 与 T1DM 之间关联的原始研究。进行了手动搜索以确定遗漏的研究。使用美国国立卫生研究院（NIH）的偏倚风险工具分析纳入研究的质量。结局包括住院时间、住院、重症监护病房（ICU）入院、糖尿病酮症酸中毒（DKA）、严重低血糖和死亡。
15 项研究纳入定性分析。纳入的研究报告了成人和儿科患者的数据。COVID-19 患者中 T1DM 的患病率为 0.15%至 28.98%，而 T1DM 患者中 COVID-19 的发生率为 0%至 16.67%。干咳、恶心、呕吐、发热和血糖升高是最常报告的表现。研究人群中调查的结局差异很大。
COVID-19 患者中 T1DM 的患病率为 0.15%至 28.98%。T1DM 患者 COVID-19 的最常见表现包括发热、干咳、恶心和呕吐、血糖升高和糖尿病酮症酸中毒。纳入研究报告的 COVID-19 住院时间、住院、ICU 入院、DKA 发生率和严重低血糖的结局差异很大。由于研究人群存在异质性且存在许多局限性，仍需要更多的研究来得出明确的结论。
Zotero 插件